Seizures remain uncontrolled in one third of patients with focal epilepsy, despite the introduction of third-generation anti-epileptic drugs (AED) with varying modes of action [1,2]. During first-line AED treatment, about 50% of patients experience at least one adverse event [3,4]. Thus, new treatment methods are needed to improve seizure control while not affecting the patient’s quality of life by adverse effects [5]. One approach is the improvement of antiepileptic drugs with proven clinical efficacy by enhancing their pharmacodynamics potency [6].
29
JUL
JUL
0